Penumbra, Inc.
Financials
Valuation Metrics
Penumbra, Inc.'s Market Cap is $12.64B. At end of 2025 it was $12.18B. Ranked #788 of 3,118 in US market (top 25%), #542 of 1,644 on NYSE (top 33%), #54 of 203 in Health Care Equipment & Services (top 27%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $12.64B | US#788/3,118 Sec#54/203 |
| Revenue | $1.56B | US#1,604/3,118 Sec#98/203 |
| Net Income | $157M | US#1,398/3,118 Sec#71/203 |
| Total Assets | $2.03B | US#2,090/3,118 Sec#106/203 |
| Net Assets | $1.58B | US#1,451/3,118 Sec#74/203 |
| Employees | 4,700 | US#1,253/3,118 Sec#90/203 |
| Value | ||
| P/E | 80.50x | US#2,040/3,118 Sec#108/203 |
| P/B | 7.98x | US#2,542/3,118 Sec#160/203 |
| P/S | 8.10x | US#2,627/3,118 Sec#176/203 |
| EV/EBITDA | 54.95x | US#2,374/3,118 Sec#130/203 |
| FCF Yield | 1.58% | US#2,066/3,118 Sec#126/203 |
| Profitability | ||
| ROE | 9.92% | US#1,308/3,118 Sec#65/203 |
| ROA | 7.75% | US#645/3,118 Sec#37/203 |
| Op. Margin | 12.13% | US#1,380/3,118 Sec#57/203 |
| Revenue Growth | 16.98% | US#780/3,118 Sec#50/203 |
| Earnings Growth | -4.27% | US#1,105/3,118 Sec#61/203 |
| Financial Health | ||
| Debt Ratio | 27.89% | US#324/3,118 Sec#32/203 |
| Total Debt | $209M | US#2,215/3,118 Sec#120/203 |
| FCF | $200M | US#1,341/3,118 Sec#80/203 |
| Cash | $254M | US#1,708/3,118 Sec#101/203 |
| Current Ratio | 5.89x | US#403/3,118 Sec#31/203 |
| Net Debt/EBITDA | -0.20x | US#602/3,118 Sec#46/203 |
| Performance | ||
| 1Y Return | 41.33% | US#687/3,118 Sec#64/203 |
| 1M Return | 1.20% | US#1,733/3,118 Sec#131/203 |
| From 52W High | -11.33% | US#934/3,118 Sec#79/203 |
| 1Y MDD | -12.23% | US#112/3,118 Sec#3/203 |
| Trading | ||
| Volume | 426,820 shares | US#2,163/3,118 Sec#153/203 |
| Trading Value | $137M | US#724/3,118 Sec#60/203 |
| Per Share | ||
| EPS | $3.99 | US#831/3,118 Sec#45/203 |
| BPS | $40.26 | US#641/3,118 Sec#44/203 |
Company Info
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.